TSXV:CLAS.H - Post by User
Post by
indaknownewfieon Jun 14, 2018 9:52pm
![](https://assets.stockhouse.com/kentico-cms/0340-00/images/Sprite.svg#id_Post_Views_Icon)
123 Views
Post# 28175627
GW PHARMA - June 27th
GW PHARMA - June 27th Will Epidiolex Give GW Pharma New Highs?
Company: GW Pharmaceuticals (NASDAQ: GWPH)
- Type of Application: NDA
- Candidate: Epidiolex
- Indication: Adjunctive treatment of seizures, with Lennox-Gastaut syndrome (LGS) and Dravet
- Date: June 27
FDA's Peripheral and Central Nervous System Drugs Advisory Committee, which met in April, unanimously recommended supporting the approval of epidiolex, which is purified plant-based cannabidiol oral solution (CBD) lacking the high associated with marijuana.
Read more at https://www.stockhouse.com/news/press-releases/2018/06/01/attention-biotech-investors-mark-your-calendar-for-these-june-pdufa-dates#EwuVmM2wbfbOMiEU.99